Morgan Stanley has upgraded Amicus Therapeutics (FOLD, Financial) from an "Equal Weight" to an "Overweight" rating. The investment firm has set a price target for the stock at $12. This change in rating suggests a more optimistic outlook on the company's future performance by the analysts at Morgan Stanley.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Amicus Therapeutics Inc (FOLD, Financial) is $15.67 with a high estimate of $22.00 and a low estimate of $9.00. The average target implies an upside of 158.10% from the current price of $6.07. More detailed estimate data can be found on the Amicus Therapeutics Inc (FOLD) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Amicus Therapeutics Inc's (FOLD, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Amicus Therapeutics Inc (FOLD, Financial) in one year is $20.76, suggesting a upside of 242.01% from the current price of $6.07. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Amicus Therapeutics Inc (FOLD) Summary page.
